Evidence map›Paper›PMID 33785775›Full record

ArticleScientific reports2021

Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death.

Victoria D Turubanova, Tatiana A Mishchenko, Irina V Balalaeva, Iuliia Efimova, Nina N Peskova, Larisa G Klapshina, Svetlana A Lermontova, Claus Bachert, Olga Krysko, Maria V Vedunova and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 56 citations in OpenAlex.

  1. Shedding light on the cancer cell death mechanism in photodynamic therapy.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Involvement of HMGB1-mediated ferroptosis in systemic diseases.Frontiers in cell and developmental biology · 2025
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Victoria D TurubanovaInstitute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.
Tatiana A MishchenkoInstitute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.
Irina V BalalaevaInstitute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.
Iuliia EfimovaCell Death Investigation and Therapy Laboratory, Department of Human Structure and Repair, Ghent University, C. Heymanslaan 10, Building B3, 4th Floor, 9000, Ghent, Belgium.
Nina N PeskovaInstitute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.
Larisa G KlapshinaG.A. Razuvaev Institute of Organometallic Chemistry of the Russian Academy of Sciences, Nizhny Novgorod, Russian Federation.
Svetlana A LermontovaG.A. Razuvaev Institute of Organometallic Chemistry of the Russian Academy of Sciences, Nizhny Novgorod, Russian Federation.
Claus BachertUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
Olga KryskoUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
Maria V VedunovaInstitute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation.
Dmitri V KryskoInstitute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation. dmitri.krysko@ugent.be.
N. I. Lobachevsky State University of Nizhny Novgorod · RUCancer Research Institute Ghent · BEG.A. Razuvaev Institute of Organometallic Chemistry · RUGhent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunogenicity of dying cancer cells determines the efficacy of anti-cancer therapy. Photodynamic therapy (PDT) can induce immunogenic cell death (ICD), which is characterized by the emission of damage-associated molecular patterns (DAMPs) from dying cells. This emission can trigger effective anti-tumor immunity. Only a few photosensitizers are known to induce ICD and, therefore, there is a need for development of new photosensitizers that can induce ICD. The purpose of this work was to analyze whether photosensitizers developed in-house from porphyrazines (pz I and pz III) can induce ICD in vitro and in vivo when used in PDT. We indetified the optimal concentrations of the photosensitizers and found that, at a light dose of 20 J/cm

Indexed as

AnimalsCell DeathCell Line, TumorImmunogenic Cell DeathMiceMice, Inbred C57BLNeoplasmsPhotochemotherapyPhotosensitizing AgentsPhotosensitizing Agents

Identifiers

PMID33785775
PMCPMC8010109
OpenAlexW3148336754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.